Patients with many hematologic tumors, including AML, have expression of LCN2 (Bouchet and Bauvois, 2014; Candido et al., 2014), which is required for the BCR-ABL-induced mouse leukemia model and is involved in damaging normal hematopoietic cells and inducing tissue invasion by leukemia cells (Leng et al., 2008). This evidence concerns the gene LCN2 and leukemia.